Status: Not yet recruiting
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral arbaclofen ER tablets in MS patients with spasticity. Arbaclofen ER will be compared with placebo.
Participants needed: 442
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: RVL Pharmaceuticals, Inc.Updated: Dec 3, 2025
Eligibility criteria
Subjects 18 to 65 years of age, inclusive [+6]
Any concomitant disease or disorder that has symptoms of spasticity or that may... [+6]